Cargando…

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease

Alzheimer’s disease (AD) is a chronic pathological condition that leads to neurodegeneration, loss of intellectual abilities, including cognition and memory, and ultimately to death. It is widely recognized that AD is a multifactorial disease, where different pathological cascades (mainly amyloid an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reggiani, Angelo M., Simoni, Elena, Caporaso, Roberta, Meunier, Johann, Keller, Emeline, Maurice, Tangui, Minarini, Anna, Rosini, Michela, Cavalli, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016838/ https://www.ncbi.nlm.nih.gov/pubmed/27609215 http://dx.doi.org/10.1038/srep33172

Ejemplares similares

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity
por: Lopes, João P, et al.
Publicado: (2013)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
por: Koola, Maju Mathew
Publicado: (2016)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Polyamine Conjugation as a Promising Strategy To Target Amyloid Aggregation in the Framework of Alzheimer’s Disease
por: Simoni, Elena, et al.
Publicado: (2016)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Arne
por: Björnson, Björnstjerne, 1832-1910
Publicado: (1959)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Arne Jacobsen
por: Jacobsen, Arne

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Polyamine–Drug Conjugates: Do They Boost Drug Activity?
por: Basagni, Filippo, et al.
Publicado: (2023)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

The Phosphatase PP2A Interacts With ArnA and ArnB to Regulate the Oligomeric State and the Stability of the ArnA/B Complex
por: Ye, Xing, et al.
Publicado: (2020)

Corrigendum: The Phosphatase PP2A Interacts With ArnA and ArnB to Regulate the Oligomeric State and the Stability of the ArnA/B Complex
por: Ye, Xing, et al.
Publicado: (2020)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Arne Jacobsen : obras y proyectos = works and projects
por: Solaguren-Beascoa de Corral, Félix
Publicado: (1989)

Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-β Peptide Injection in Rats
por: Zussy, Charleine, et al.
Publicado: (2013)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Inhibition of β-Amyloid Aggregation in Alzheimer’s Disease: The Key Role of (Pro)electrophilic Warheads
por: Basagni, Filippo, et al.
Publicado: (2022)

Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease
por: Belitskaya-Lévy, Ilana, et al.
Publicado: (2018)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment
por: Wang, Xiaochuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_isuu7ri2c8hfvkvo3dedln8fkd